Summit X LLC Buys 644 Shares of Merck & Co., Inc. $MRK

Summit X LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 21.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,639 shares of the company’s stock after buying an additional 644 shares during the quarter. Summit X LLC’s holdings in Merck & Co., Inc. were worth $288,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in MRK. Charles Schwab Investment Management Inc. lifted its holdings in Merck & Co., Inc. by 144.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after buying an additional 29,104,112 shares during the period. Nuveen LLC bought a new position in shares of Merck & Co., Inc. in the 1st quarter worth about $991,553,000. Pacer Advisors Inc. boosted its holdings in Merck & Co., Inc. by 2,240.9% in the first quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company’s stock worth $474,543,000 after acquiring an additional 5,060,959 shares in the last quarter. Amundi increased its position in Merck & Co., Inc. by 37.1% during the first quarter. Amundi now owns 13,077,716 shares of the company’s stock valued at $1,130,397,000 after acquiring an additional 3,542,036 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at $258,267,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.7%

MRK opened at $86.34 on Monday. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $105.07. The business has a 50 day moving average price of $84.59 and a two-hundred day moving average price of $82.08. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The company has a market cap of $214.30 billion, a PE ratio of 13.30, a P/E/G ratio of 0.95 and a beta of 0.34.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.22. The firm had revenue of $17.28 billion during the quarter, compared to analysts’ expectations of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.Merck & Co., Inc.’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analysts Forecast Growth

MRK has been the topic of several analyst reports. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $104.47.

Insider Activity

In other news, EVP David Michael Williams sold 8,614 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.